SCHEMBL2460044

SCHEMBL2460044

CCOC(=O)n1nc(NC(=O)c2ccc(N(C)C)cc2[N+](=O)[O-])c2c1CCN(S(=O)(=O)c1cc(F)cc(F)c1)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPT P10636 6/20 0.35
ALDH1A1 P00352 6/20 0.35
USP2 O75604 3/20 0.35
HSD17B10 Q99714 2/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
POLB P06746 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
TRPV4 Q9HBA0 1/20 0.35
LMNA P02545 7/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
KDM4E B2RXH2 2/20 0.33
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887029 0.93 IGF1R (0.36) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL1885175 0.90 IGF1R (0.38) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL1895529 0.89 ALDH1A1 (0.40) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL2458979 0.89 IGF1R (0.39) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL2458396 0.88 MAPT (0.35) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL1894731 0.87 IGF1R (0.50) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL1890200 0.87 IGF1R (0.43) IGF1RKMT2AMEN1MAPTALDH1A1
SCHEMBL1883184 0.85 IGF1R (0.39) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL1888067 0.84 IGF1R (0.42) IGF1RKMT2AMEN1L3MBTL1MAPT
SCHEMBL1885047 0.84 IGF1R (0.39) IGF1RKMT2AMEN1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885KMT2A 1468/4885MEN1 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.